Conti Federal Named to $990 Indo-Pacific Indefinite Delivery, Indefinite Quantity Multiple Award Construction Contract for Projects in the NAVFAC Pacific Area of Operations
'Expanding our footprint under the Indo-Pacific MACC reinforces our long-standing commitment to supporting NAVFAC's global mission,' said Jason Roberts, Regional Business Development Director – Pacific.
Share
The $990M IDIQ MACC includes Design-Build (DB) and Design-Bid-Build (DBB) construction services for new facilities, renovations, repairs, and infrastructure upgrades. Project scopes encompass airfield paving, waterfront construction, and a variety of base infrastructure improvements. These efforts support the Pacific Deterrence Initiative, including Exercise Related Construction (ERC), Unspecified Minor Military Construction (UMMC), U.S. Code Title 10 Security Cooperation, and other repair projects across the NAVFAC Pacific area of operations.
Anticipated project locations include the Caroline Islands, Philippines, Northern Territory of Australia, Papua New Guinea, Timor-Leste, Singapore, Malaysia, Thailand, Indonesia, Vietnam, Nepal, Sri Lanka, Fiji, and the Maldives.
'Expanding our footprint under the Indo-Pacific MACC reinforces our long-standing commitment to supporting NAVFAC's global mission,' said Jason Roberts, Regional Business Development Director – Pacific. 'We're proud to bring our proven capabilities to get the job Done Once, Done Right and agile teams to deliver critical infrastructure across the region with excellence and reliability."
Conti Federal brings experience in the Indo-Pacific region, with recent projects including a building renovation at Camp Hansen in Okinawa, Japan, and a fuel system repair at Andersen Air Force Base in Guam. With offices and projects spanning multiple continents, the company is well-positioned to support the U.S. federal government's global infrastructure needs.
To view the company's locations, visit https://www.contifederal.com/about/locations/.
About Conti Federal Services
Conti Federal Services is a leading global construction and engineering company with roots dating back to 1906. The company has delivered some of the most demanding projects for the U.S. federal government, specializing in military and secure construction, critical infrastructure, environmental remediation, and disaster response and recovery. Conti Federal is dedicated to ensuring clients meet mission success while committing to its core values of safety, integrity, and compliance. To learn more, visit www.contifederal.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
Strategic Collaborations and Local Innovations Reshape the $24.58 Billion Market
The Asia Pacific diabetes market is set for growth, expected to expand annually by 8.8% to reach $24.58 billion by 2025. Significant trends include increased diabetes prevalence and digital health adoption, driving demand for monitoring and therapeutic solutions. Enhanced policy reforms and insurance coverage are fostering market access, while rising competition is reshaping the landscape with strategic alliances and localized innovation. The comprehensive report analyzes diagnosis and monitoring devices and therapeutics, exploring market dynamics and opportunities. Get insights on the competitive environment, segment growth, and investment potential within the diabetes market in Asia Pacific. Asia-Pacific Diabetes Devices and Therapeutics Market Dublin, July 08, 2025 (GLOBE NEWSWIRE) -- The "Asia-Pacific Diabetes Devices and Therapeutics Market Investment Opportunities - Q2 2025 Update" report has been added to diabetes market in Asia Pacific is expected to grow by 8.8% on annual basis to reach US$24.58 billion in 2025. The diabetes market in the region has experienced robust growth during 2020-2024, achieving a CAGR of 9.4%. This upward trajectory is expected to continue, with the market forecast to grow at a CAGR of 7.4% during 2025-2029. By the end of 2029, the diabetes market is projected to expand from its 2024 value of USD 22.59 billion to approximately USD 35.43 billion. This report provides a detailed data-centric analysis of the diabetes industry in Asia Pacific, covering market opportunities and analysis across a range of diagnosis and monitoring devices, therapeutics, domains. With over 50+ KPIs at the country level, this report provides a comprehensive understanding of diabetes market dynamics, market size and forecast, and market share statistics. The market features participation from both established multinational corporations and emerging regional manufacturers. The competitive environment is characterized by varied regulatory frameworks and economic conditions across the Asia Pacific. Publications from the past 12 months indicate a segmented market with regional differentiation in product offerings and market strategies. The market is evolving with a mix of longstanding multinational entities and agile local innovators. With an expected trend toward consolidation and strategic collaborations, the next 2-4 years will likely see a reshaping of competitive dynamics focused on localized product innovation and regulatory alignment. The diabetes devices and therapeutics market in Asia Pacific is being reshaped by increased diabetes prevalence, the adoption of digital health solutions, and evolving policy frameworks. These drivers are expected to intensify over the next 2-4 years, leading to more targeted and data-supported approaches in managing diabetes across diverse regional Rising Diabetes Prevalence and Healthcare Demand Recent publications (2023-2024) report a measurable increase in diabetes cases across Asia Pacific, with significant examples in China, India, and several Southeast Asian nations. Rising incidences of type 2 diabetes are increasing the need for effective monitoring and therapeutic interventions. Demographic shifts (aging populations, urbanization) and evolving lifestyle patterns drive the demand. Adjustments in healthcare financing and insurance reforms across the region support wider access to diagnostic devices and therapies. Anticipate a steady intensification in demand for devices that integrate daily management tools. Healthcare systems will likely expand investments in diabetes-related technologies to address the growing burden. Leverage Digital Integration and Remote Monitoring Solutions Recent regional studies highlight the increased adoption of continuous glucose monitoring (CGM) systems and telehealth services, especially in Japan and South Korea. Various Asia Pacific markets have initiated pilot programs integrating remote monitoring with traditional care models. Technological progress and supportive regulatory policies in digital health are key drivers. Increased investments in digital infrastructure by governments and insurers foster the adoption of connected devices. Expect further penetration of digital health solutions, with remote monitoring playing a more central role in clinical decision-making. Enhanced data analytics are likely to support more personalized diabetes management strategies regionally. Activate Policy Reforms and Insurance Coverage Enhancements Recent reforms in countries like Singapore and Australia have expanded reimbursement for diabetes management devices. Publications from late 2023 detail shifts in regulatory frameworks that now favor broader insurance coverage for innovative therapeutics. Government initiatives focused on reducing long-term healthcare expenditures and improving chronic disease management drive policy changes. Broader insurance reforms align with healthcare objectives to support preventive care and early intervention. The convergence of supportive policies and insurance incentives will further facilitate market access for new devices and therapies. Ongoing regulatory clarifications will likely encourage domestic and international investments in the region. Map Key Players and New Entrants Major global companies continue investing in research and development to maintain their regional presence. Local manufacturers, particularly in India and China, are entering the market with products tailored to regional cost structures and clinical needs. New entrants are leveraging localized expertise to address gaps in the current market, supported by regional demand for cost-effective solutions. Evaluate Strategic Collaborations and Market Consolidation Recent transactions in the last 12 months have seen collaborations between device manufacturers and healthcare providers in Southeast Asia and Australia. Strategic alliances emerge as companies seek to expand their product portfolios and market reach through mergers and acquisitions. The competitive landscape will likely experience increased consolidation as larger players acquire or partner with regional innovators. Firms that successfully navigate regulatory requirements and invest in localized development are positioned to gain competitive advantages. Forecast Competitive Shifts Continued regulatory reforms and heightened demand for diabetes management solutions will attract further competition. Specialized product developments addressing country-specific needs may lead to a more segmented competitive environment. Investment in research, strategic partnerships, and adaptation to local regulatory environments will be critical for sustaining market leadership. A bundled offering, combining the following 12 reports, covering 480 tables and 648 figures: Asia Pacific Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook) Australia Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook) China Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook) India Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook) Indonesia Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook) Japan Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook) Malaysia Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook) Philippines Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook) Singapore Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook) South Korea Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook) Taiwan Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook) Thailand Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook) Scope for Each Report Diabetes Devices and Therapeutics Market Share by Category Diagnosis and Monitoring Devices Therapeutics Diabetes Devices and Therapeutics Market Share by Diagnosis and Monitoring Devices Blood Glucose Monitoring Devices Insulin Delivery Devices Diabetes Management and Mobile Applications Artificial Pancreas Devices Diabetes Devices and Therapeutics Market Share by Blood Glucose Monitoring Devices Self-Monitoring Blood Glucose Devices Continuous Blood Glucose Monitoring Devices Test Strips Lancets Diabetes Devices and Therapeutics Market Share by Insulin Delivery Devices Insulin Pumps Insulin Pens Insulin Syringes Diabetes Devices and Therapeutics Market Share by Therapeutics Oral Anti-Diabetic Drugs Insulin Non-Insulin Injectable Drugs Combination Drugs Diabetes Devices and Therapeutics Market Share by Oral Anti-Diabetic Drugs Alpha-Glucosidase Inhibitors DPP-4 Inhibitors SGLT-2 Inhibitors Diabetes Devices and Therapeutics Market Share by Insulin Basal or Long-Acting Bolus or Fast-Acting Traditional Human Insulin Drugs Insulin Biosimilars Diabetes Devices and Therapeutics Market Share by Non-Insulin Injectable Drugs GLP-1 Receptor Agonists Amylin Analogue Diabetes Devices and Therapeutics Market Share by Combination Drugs Combination Insulin Oral Combination Diabetes Devices and Therapeutics Market Share by Route of Administration Subcutaneous Intravenous Others Diabetes Devices and Therapeutics Market Share by Type of Diabetes Type 1 Diabetes Type 2 Diabetes Diabetes Devices and Therapeutics Market Share by Distribution Channels Online Pharmacies Hospital Pharmacies Retail Pharmacies Diabetes Devices and Therapeutics Market Share by End User Hospitals Diabetes Clinics Homecare Reasons to buy Comprehensive understanding of market structure and dynamics: Gain a detailed view of the diabetes devices and therapeutics market, including category-level segmentation (Diagnosis & Monitoring Devices and Therapeutics) and sub-segmentation by product type, route of administration, type of diabetes, distribution channel, and end user. Identify high-growth segments and strategic investment areas: Use segment-wise market sizing and forecasting to identify opportunities in areas such as continuous glucose monitoring, insulin delivery technologies, oral anti-diabetic drugs, and biosimilars. Tailor your market entry or expansion strategies accordingly. Benchmark performance across distribution and care settings: Access share analysis across online, hospital, and retail pharmacies, and evaluate usage patterns across hospitals, diabetes clinics, and homecare to support channel-specific planning and resource allocation. Key Attributes: Report Attribute Details No. of Pages 840 Forecast Period 2025 - 2029 Estimated Market Value (USD) in 2025 $26.63 Billion Forecasted Market Value (USD) by 2029 $35.43 Billion Compound Annual Growth Rate 7.4% Regions Covered Asia Pacific For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Asia-Pacific Diabetes Devices and Therapeutics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 hours ago
- Yahoo
Sino Biopharma spends $951m to acquire China-based LaNova Medicines
Hong Kong-listed Sino Biopharmaceutical will acquire China-based oncology specialist LaNova Medicines in a deal that will not exceed $951m, representing one of the largest transactions within the Asia-Pacific pharmaceutical arena this year. Sino already owns a 4.91% stake courtesy of an investment in November 2024, with the company now seeking to purchase the remaining 95.09% it does not own. At the time, Sino spent 142 million yuan ($19.80m) to initiate its ownership involvement with the biotech. The net payment made by Sino to acquire LaNova will be approximately $500.9m, a figure that excludes the estimated cash and bank deposits, according to a company document outlining the terms of the transaction. Following the completion of the nearly billion-dollar deal, LaNova Medicines will become an indirect wholly owned subsidiary of Sino. A timeline of 30 business days has been set by the companies to finalise the deal. Sino revealed the acquisition agreement after trading hours on 15 July. The share price in the company had climbed 3.6% by market close. LaNova's drug development focuses on tumour immunity and the tumour microenvironment. The company has particular emphasis on antibody-drug conjugates (ADCs) and has built several platforms within this modality. Sino stated the acquisition would strengthen its research and development capabilities, subsequently enhancing competitiveness and innovation in the oncology market. LaNova's pipeline has already been raided twice by US big pharma companies. In 2023, AstraZeneca licensed LM-305, a G-protein targeting-ADC, for $600m. A year later, MSD outlaid more than $3bn to secure global rights to LM-299, an anti-PD-1/VEGF bispecific antibody. According to Sino, LaNova Medicines has two projects in the registration clinical stage, six projects in the Phase I/II clinical trial stage, and more than ten projects in the preclinical research stage. In a statement, Sino said: 'Through the in-depth synergy and integration of the advantageous resources of both parties, not only will the potential value of LaNova Medicines be fully released, but also [Sino's] innovation capability will be comprehensively enhanced." The company added that the transaction will help towards its 'strategic goal of advancing towards a world-class innovative pharmaceutical enterprise'. China's economy grew 5.2% year-on-year in Q2, defying the lingering effects of US President Trump's trade war and reinforcing its position as the world's top exporter. This economic resilience is mirrored in China's growing role in the global oncology market. Despite economic pressures, licensing promising drug candidates from Chinese biotechs is becoming a well-trodden path for many US big pharma companies. Licensing deals between US and Chinese biopharma companies hit record highs last year, a 280% increase from 2020, according to analysis by GlobalData. Across big pharma, transactions rose 66% from $16.6bn in 2023 to $41.5bn in 2024, demonstrating that China is still the go-to place to discover pipeline candidates. For deals specific to US companies, the analysis found that total deal value rose from $15.7bn in 2023 to $21.3bn in 2024. GlobalData is the parent company of Pharmaceutical Technology. "Sino Biopharma spends $951m to acquire China-based LaNova Medicines" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
CNN
7 hours ago
- CNN
Trump says he's reached a trade agreement with Indonesia but offers no details
President Donald Trump said Tuesday the administration has reached a trade agreement with Indonesia, but he offered no details, including how comprehensive a deal might be, any possible terms or when any provisions might take effect. 'Great deal, for everybody, just made with Indonesia. I dealt directly with with their highly respected President,' Trump wrote on his social media platform. 'DETAILS TO FOLLOW!!!' This marks Trump's fourth trade agreement announcement in three months. However, he and the administration promised to make several more deals that have failed to come to fruition. This is a developing story and will be updated.
